Correction to : Cardiovascular Drugs and Therapy
The original article has been corrected. References 5 and 6 have been switched. Reference 5 “Bhatt DL, Szarek M, Steg PG, et al. Sotagliflozin in patients with diabetes and worsening heart failure. N Eng J Med. 2021;384:117–28” should be “Bhatt DL, Szarek M, Pitt B, et al. Sotagliflozin in patients with diabetes and chronic kidney disease. N Eng J Med. 2021;384:129–39.” Reference 6 “Bhatt DL, Szarek M, Pitt B, et al. Sotagliflozin in patients with diabetes and chronic kidney disease. N Eng J Med. 2021;384:129–39” should be “Bhatt DL, Szarek M, Steg PG, et al. Sotagliflozin in patients with diabetes and worsening heart failure. N Eng J Med. 2021;384:117–28.”
5. Bhatt DL, Szarek M, Pitt B, et al. Sotagliflozin in patients with diabetes and chronic kidney disease. N Eng J Med. 2021;384:129–39.
6. Bhatt DL, Szarek M, Steg PG, et al. Sotagliflozin in patients with diabetes and worsening heart failure. N Eng J Med. 2021;384:117–28.
Author information
Authors and Affiliations
Corresponding author
Additional information
Publisher's Note
Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.
Rights and permissions
About this article
Cite this article
Pitt, B., Steg, G., Leiter, L.A. et al. Correction to: The Role of Combined SGLT1/SGLT2 Inhibition in Reducing the Incidence of Stroke and Myocardial Infarction in Patients with Type 2 Diabetes Mellitus. Cardiovasc Drugs Ther 36, 1259 (2022). https://doi.org/10.1007/s10557-021-07308-6
Published:
Issue Date:
DOI: https://doi.org/10.1007/s10557-021-07308-6